Prescription monitoring programs and emergency department visits involving benzodiazepine misuse

Early evidence from 11 United States metropolitan areas

Marcus A. Bachhuber, Brandon Maughan, Nandita Mitra, Jordyn Feingold, Joanna L. Starrels

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Emergency department (ED) visits involving benzodiazepines have increased in the United States. Most states have created prescription monitoring programs (PMPs) to improve drug prescribing safety. To determine the association between PMP implementation and ED visits involving benzodiazepine misuse, we conducted a retrospective analysis of data from 11 metropolitan areas in the United States from 2004 to 2011. Methods: We estimated rates of ED visits per 100,000 residents involving benzodiazepine misuse from the Drug Abuse Warning Network dataset. Dates of PMP implementation were obtained from program administrators. We used linear regression models to assess whether PMP implementation was associated with a change in ED visits involving benzodiazepines. Models were adjusted for calendar quarter, metropolitan area, and metropolitan area-specific linear time trends. Results: Rates of ED visits involving benzodiazepine misuse increased in all metropolitan areas during the study period. PMP implementation was not associated with a change in ED visits (mean difference: 0.9 [95% CI: -0.09 to 1.9] visits per 100,000 population per quarter; p = 0.08). When analyzed by number of years after implementation, PMPs were associated with a higher visit rate in year one (0.8 [95% CI: 0.2-1.5]; p = 0.01]), but not in year two (0.3 [95% CI: -2.1-2.8]; p = 0.78) or year three or later (2.1 [95% CI: -0.4-4.7]; p = 0.10). Conclusion: We did not find evidence that PMP implementation was associated with reductions in ED visits involving benzodiazepine misuse. Future work should identify PMP features and capabilities that improve benzodiazepine safety.

Original languageEnglish (US)
Pages (from-to)120-123
Number of pages4
JournalInternational Journal of Drug Policy
Volume28
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

Fingerprint

Benzodiazepines
Prescriptions
Hospital Emergency Service
Linear Models
Safety
Drug Prescriptions
Administrative Personnel
Substance-Related Disorders
Population

Keywords

  • Benzodiazepines
  • Health policy
  • Prescription drug misuse
  • Public health
  • Public policy

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Health Policy

Cite this

Prescription monitoring programs and emergency department visits involving benzodiazepine misuse : Early evidence from 11 United States metropolitan areas. / Bachhuber, Marcus A.; Maughan, Brandon; Mitra, Nandita; Feingold, Jordyn; Starrels, Joanna L.

In: International Journal of Drug Policy, Vol. 28, 01.02.2016, p. 120-123.

Research output: Contribution to journalArticle

@article{7ea6b4e249e942baa20b20f25e675c12,
title = "Prescription monitoring programs and emergency department visits involving benzodiazepine misuse: Early evidence from 11 United States metropolitan areas",
abstract = "Background: Emergency department (ED) visits involving benzodiazepines have increased in the United States. Most states have created prescription monitoring programs (PMPs) to improve drug prescribing safety. To determine the association between PMP implementation and ED visits involving benzodiazepine misuse, we conducted a retrospective analysis of data from 11 metropolitan areas in the United States from 2004 to 2011. Methods: We estimated rates of ED visits per 100,000 residents involving benzodiazepine misuse from the Drug Abuse Warning Network dataset. Dates of PMP implementation were obtained from program administrators. We used linear regression models to assess whether PMP implementation was associated with a change in ED visits involving benzodiazepines. Models were adjusted for calendar quarter, metropolitan area, and metropolitan area-specific linear time trends. Results: Rates of ED visits involving benzodiazepine misuse increased in all metropolitan areas during the study period. PMP implementation was not associated with a change in ED visits (mean difference: 0.9 [95{\%} CI: -0.09 to 1.9] visits per 100,000 population per quarter; p = 0.08). When analyzed by number of years after implementation, PMPs were associated with a higher visit rate in year one (0.8 [95{\%} CI: 0.2-1.5]; p = 0.01]), but not in year two (0.3 [95{\%} CI: -2.1-2.8]; p = 0.78) or year three or later (2.1 [95{\%} CI: -0.4-4.7]; p = 0.10). Conclusion: We did not find evidence that PMP implementation was associated with reductions in ED visits involving benzodiazepine misuse. Future work should identify PMP features and capabilities that improve benzodiazepine safety.",
keywords = "Benzodiazepines, Health policy, Prescription drug misuse, Public health, Public policy",
author = "Bachhuber, {Marcus A.} and Brandon Maughan and Nandita Mitra and Jordyn Feingold and Starrels, {Joanna L.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.drugpo.2015.08.005",
language = "English (US)",
volume = "28",
pages = "120--123",
journal = "International Journal of Drug Policy",
issn = "0955-3959",
publisher = "Elsevier",

}

TY - JOUR

T1 - Prescription monitoring programs and emergency department visits involving benzodiazepine misuse

T2 - Early evidence from 11 United States metropolitan areas

AU - Bachhuber, Marcus A.

AU - Maughan, Brandon

AU - Mitra, Nandita

AU - Feingold, Jordyn

AU - Starrels, Joanna L.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background: Emergency department (ED) visits involving benzodiazepines have increased in the United States. Most states have created prescription monitoring programs (PMPs) to improve drug prescribing safety. To determine the association between PMP implementation and ED visits involving benzodiazepine misuse, we conducted a retrospective analysis of data from 11 metropolitan areas in the United States from 2004 to 2011. Methods: We estimated rates of ED visits per 100,000 residents involving benzodiazepine misuse from the Drug Abuse Warning Network dataset. Dates of PMP implementation were obtained from program administrators. We used linear regression models to assess whether PMP implementation was associated with a change in ED visits involving benzodiazepines. Models were adjusted for calendar quarter, metropolitan area, and metropolitan area-specific linear time trends. Results: Rates of ED visits involving benzodiazepine misuse increased in all metropolitan areas during the study period. PMP implementation was not associated with a change in ED visits (mean difference: 0.9 [95% CI: -0.09 to 1.9] visits per 100,000 population per quarter; p = 0.08). When analyzed by number of years after implementation, PMPs were associated with a higher visit rate in year one (0.8 [95% CI: 0.2-1.5]; p = 0.01]), but not in year two (0.3 [95% CI: -2.1-2.8]; p = 0.78) or year three or later (2.1 [95% CI: -0.4-4.7]; p = 0.10). Conclusion: We did not find evidence that PMP implementation was associated with reductions in ED visits involving benzodiazepine misuse. Future work should identify PMP features and capabilities that improve benzodiazepine safety.

AB - Background: Emergency department (ED) visits involving benzodiazepines have increased in the United States. Most states have created prescription monitoring programs (PMPs) to improve drug prescribing safety. To determine the association between PMP implementation and ED visits involving benzodiazepine misuse, we conducted a retrospective analysis of data from 11 metropolitan areas in the United States from 2004 to 2011. Methods: We estimated rates of ED visits per 100,000 residents involving benzodiazepine misuse from the Drug Abuse Warning Network dataset. Dates of PMP implementation were obtained from program administrators. We used linear regression models to assess whether PMP implementation was associated with a change in ED visits involving benzodiazepines. Models were adjusted for calendar quarter, metropolitan area, and metropolitan area-specific linear time trends. Results: Rates of ED visits involving benzodiazepine misuse increased in all metropolitan areas during the study period. PMP implementation was not associated with a change in ED visits (mean difference: 0.9 [95% CI: -0.09 to 1.9] visits per 100,000 population per quarter; p = 0.08). When analyzed by number of years after implementation, PMPs were associated with a higher visit rate in year one (0.8 [95% CI: 0.2-1.5]; p = 0.01]), but not in year two (0.3 [95% CI: -2.1-2.8]; p = 0.78) or year three or later (2.1 [95% CI: -0.4-4.7]; p = 0.10). Conclusion: We did not find evidence that PMP implementation was associated with reductions in ED visits involving benzodiazepine misuse. Future work should identify PMP features and capabilities that improve benzodiazepine safety.

KW - Benzodiazepines

KW - Health policy

KW - Prescription drug misuse

KW - Public health

KW - Public policy

UR - http://www.scopus.com/inward/record.url?scp=84958111003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958111003&partnerID=8YFLogxK

U2 - 10.1016/j.drugpo.2015.08.005

DO - 10.1016/j.drugpo.2015.08.005

M3 - Article

VL - 28

SP - 120

EP - 123

JO - International Journal of Drug Policy

JF - International Journal of Drug Policy

SN - 0955-3959

ER -